ArticleBreast cancer research and treatment2025
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWith limited lifestyle interventions available for women with metastatic breast cancer, we aimed to evaluate feasibility of a combined prolonged overnight fasting and exercise intervention in women with hormone receptor-positive metastatic breast cancer initiating treatment.
methodsWomen with metastatic breast cancer initiating endocrine therapy plus targeted therapy were included in a single-arm pilot trial testing a combined 12-week prolonged nightly fasting and exercise intervention. Fasting goals included abstaining from calorie intake after 8 pm and fasting for 13 + hours 6 days per week; weekly exercise goals were 120 min of home-based aerobic exercise and 2 sessions of resistance exercise. Primary outcome was feasibility; secondary outcomes included patient-reported outcomes, cardiorespiratory fitness, and physical functioning. Measures were collected at baseline and 12-week time points.
resultsThirty-one women enrolled, and 27 completed both timepoint assessments. The feasibility goal for enrollment was met with 80% of participants enrolled within the first year. The fasting intervention was well tolerated, with 74.1% of women meeting the fasting goal. Only 40.7% of women achieved the aerobic exercise goal, and 18.5% met the strength training goal. Participants experienced a significant increase in quality of life post-intervention, with improvements in emotional (+ 8.3 ± 14.2 point; p = 0.003), cognitive (+ 4.9 ± 17.2 point; p = 0.04), social functioning (+ 8.6 ± 18.1 point; p = 0.02), dyspnea (- 12.3 ± 28.0 point; p = 0.002), and insomnia (- 16.0 ± 25.1 point; p < 0.001).
conclusionThis pilot study provides insights into the feasibility, safety, and preliminary efficacy of a 12-week combined fasting and exercise intervention in women with metastatic breast cancer initiating treatment.
Indexed as
Identifiers
40794365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.